Market Closed -
OTC Markets
12:11:09 18/07/2024 am IST
|
5-day change
|
1st Jan Change
|
30.38
USD
|
-0.26%
|
|
+2.38%
|
+3.05%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
6,560
|
5,609
|
6,621
|
8,279
|
8,912
|
9,185
|
-
|
-
|
Enterprise Value (EV)
1 |
7,675
|
6,139
|
6,758
|
7,894
|
8,860
|
8,702
|
8,046
|
7,336
|
P/E ratio
|
-130
x
|
10.3
x
|
10.4
x
|
12.9
x
|
14
x
|
14.5
x
|
13.1
x
|
11.8
x
|
Yield
|
1.27%
|
1.47%
|
1.49%
|
1.19%
|
1.11%
|
1.1%
|
1.09%
|
1.1%
|
Capitalization / Revenue
|
2.55
x
|
2.16
x
|
2.31
x
|
2.74
x
|
2.85
x
|
2.66
x
|
2.49
x
|
2.34
x
|
EV / Revenue
|
2.98
x
|
2.37
x
|
2.36
x
|
2.61
x
|
2.83
x
|
2.52
x
|
2.18
x
|
1.87
x
|
EV / EBITDA
|
8.13
x
|
6.28
x
|
5.8
x
|
5.86
x
|
10.1
x
|
7.4
x
|
6.41
x
|
5.49
x
|
EV / FCF
|
15.9
x
|
8.9
x
|
8.31
x
|
9.02
x
|
12.5
x
|
15.2
x
|
10.8
x
|
9.14
x
|
FCF Yield
|
6.3%
|
11.2%
|
12%
|
11.1%
|
8.02%
|
6.59%
|
9.26%
|
10.9%
|
Price to Book
|
3.78
x
|
2.67
x
|
2.42
x
|
-
|
2.36
x
|
2.16
x
|
1.88
x
|
1.63
x
|
Nbr of stocks (in thousands)
|
83,035
|
82,601
|
82,243
|
82,380
|
82,599
|
82,599
|
-
|
-
|
Reference price
2 |
79.00
|
67.90
|
80.50
|
100.5
|
107.9
|
111.2
|
111.2
|
111.2
|
Announcement Date
|
13/02/20
|
11/02/21
|
11/02/22
|
09/02/23
|
08/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
2,576
|
2,592
|
2,869
|
3,025
|
3,128
|
3,458
|
3,691
|
3,933
|
EBITDA
1 |
943.8
|
977.5
|
1,166
|
1,348
|
881.4
|
1,177
|
1,254
|
1,335
|
EBIT
1 |
782.6
|
829.3
|
1,011
|
1,115
|
1,001
|
1,013
|
1,103
|
1,196
|
Operating Margin
|
30.38%
|
32%
|
35.25%
|
36.87%
|
32.01%
|
29.3%
|
29.88%
|
30.41%
|
Earnings before Tax (EBT)
1 |
-38.5
|
528.8
|
814.6
|
705.9
|
761.5
|
810.1
|
899.5
|
999.9
|
Net income
1 |
-50.7
|
548
|
646.6
|
647.5
|
647.2
|
637.3
|
709.4
|
788.1
|
Net margin
|
-1.97%
|
21.15%
|
22.54%
|
21.4%
|
20.69%
|
18.43%
|
19.22%
|
20.04%
|
EPS
2 |
-0.6100
|
6.570
|
7.760
|
7.810
|
7.730
|
7.670
|
8.493
|
9.423
|
Free Cash Flow
1 |
483.2
|
689.9
|
813.2
|
874.8
|
710.9
|
573.3
|
745.2
|
802.6
|
FCF margin
|
18.76%
|
26.62%
|
28.35%
|
28.92%
|
22.73%
|
16.58%
|
20.19%
|
20.41%
|
FCF Conversion (EBITDA)
|
51.2%
|
70.58%
|
69.74%
|
64.88%
|
80.66%
|
48.73%
|
59.41%
|
60.11%
|
FCF Conversion (Net income)
|
-
|
125.89%
|
125.77%
|
135.1%
|
109.84%
|
89.96%
|
105.05%
|
101.85%
|
Dividend per Share
2 |
1.000
|
1.000
|
1.200
|
1.200
|
1.200
|
1.226
|
1.211
|
1.221
|
Announcement Date
|
13/02/20
|
11/02/21
|
11/02/22
|
09/02/23
|
08/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019 S2
|
2020 S1
|
2020 S2
|
2021 S1
|
2021 Q3
|
2021 Q4
|
2021 S2
|
2022 Q1
|
2022 Q2
|
2022 S1
|
2022 Q3
|
2022 Q4
|
2022 S2
|
2023 Q1
|
2023 Q2
|
2023 S1
|
2023 Q3
|
2023 Q4
|
2023 S2
|
2024 Q1
|
2024 Q2
|
2024 S1
|
---|
Net sales
1 |
1,347
|
1,268
|
1,323
|
1,350
|
727.4
|
791.2
|
1,519
|
687.9
|
745.8
|
1,434
|
774.8
|
816.4
|
1,591
|
741.9
|
794.7
|
1,537
|
772.4
|
818.5
|
1,591
|
822.4
|
835.2
|
1,726
|
EBITDA
|
-
|
-
|
-
|
-
|
320.9
|
320.9
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
|
395.1
|
410.2
|
419.1
|
479.8
|
-
|
-
|
531.5
|
-
|
-
|
568
|
-
|
-
|
547.4
|
-
|
-
|
523.2
|
-
|
-
|
477.8
|
-
|
-
|
520
|
Operating Margin
|
29.34%
|
32.34%
|
31.67%
|
35.53%
|
-
|
-
|
35%
|
-
|
-
|
39.62%
|
-
|
-
|
34.4%
|
-
|
-
|
34.05%
|
-
|
-
|
30.03%
|
-
|
-
|
30.13%
|
Earnings before Tax (EBT)
|
-321.4
|
270.1
|
258.7
|
400.9
|
-
|
-
|
413.7
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net income
|
-271.3
|
222.7
|
325.3
|
304
|
-
|
-
|
342.6
|
-
|
-
|
-
|
-
|
-
|
253.2
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net margin
|
-20.15%
|
17.56%
|
24.58%
|
22.51%
|
-
|
-
|
22.56%
|
-
|
-
|
-
|
-
|
-
|
15.91%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
|
-3.250
|
2.660
|
3.910
|
3.640
|
-
|
-
|
4.120
|
-
|
-
|
-
|
-
|
-
|
3.070
|
-
|
-
|
2.350
|
-
|
-
|
5.380
|
-
|
-
|
3.660
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
1.200
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
13/02/20
|
30/07/20
|
11/02/21
|
29/07/21
|
11/11/21
|
11/02/22
|
11/02/22
|
27/04/22
|
28/07/22
|
28/07/22
|
27/10/22
|
09/02/23
|
09/02/23
|
27/04/23
|
27/07/23
|
27/07/23
|
26/10/23
|
08/02/24
|
08/02/24
|
24/04/24
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
1,116
|
531
|
138
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
-
|
385
|
52.9
|
483
|
1,139
|
1,849
|
Leverage (Debt/EBITDA)
|
1.182
x
|
0.5427
x
|
0.1182
x
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
483
|
690
|
813
|
875
|
711
|
573
|
745
|
803
|
ROE (net income / shareholders' equity)
|
31.3%
|
28.3%
|
26.5%
|
28.7%
|
21.4%
|
17.9%
|
16.7%
|
15.9%
|
ROA (Net income/ Total Assets)
|
-
|
12.7%
|
13.9%
|
16.5%
|
12.8%
|
10.4%
|
10.5%
|
10.1%
|
Assets
1 |
-
|
4,312
|
4,660
|
3,933
|
5,046
|
6,152
|
6,749
|
7,831
|
Book Value Per Share
2 |
20.90
|
25.40
|
33.30
|
-
|
45.60
|
51.40
|
59.30
|
68.10
|
Cash Flow per Share
2 |
7.550
|
9.250
|
10.90
|
11.70
|
10.40
|
10.40
|
11.30
|
13.80
|
Capex
1 |
145
|
81.4
|
96
|
96.6
|
116
|
118
|
117
|
126
|
Capex / Sales
|
5.61%
|
3.14%
|
3.35%
|
3.19%
|
3.72%
|
3.4%
|
3.18%
|
3.21%
|
Announcement Date
|
13/02/20
|
11/02/21
|
11/02/22
|
09/02/23
|
08/02/24
|
-
|
-
|
-
|
Last Close Price
111.2
EUR Average target price
127.3
EUR Spread / Average Target +14.46% Consensus |
1st Jan change
|
Capi.
|
---|
| +55.35% | 815B | | +32.33% | 597B | | -0.10% | 377B | | +15.47% | 319B | | +13.10% | 310B | | +16.13% | 247B | | +14.23% | 228B | | +16.54% | 180B | | +4.31% | 170B |
Other Pharmaceuticals
|